Table 2.

Peak vaccine-induced midpoint anti-gp120 titersa

Individual or groupgp120 immunogenTiterAutologous titer/heterologous titer
Anti-MN gp120Anti-SF2 gp120
C07MN6,0601,1505.3
C10MN36,6007,6104.8
C11MN54,1007,5707.1
C15MN2,93026511.1
C17MN21,2008,2902.6
C24MN48,7006,2707.8
C26MN49,75013,3403.7
C13SF-21,63012,9207.9
C16SF-211,5009,1100.8
C20SF-21053203.0
C21SF-21,2803,2702.6
 Mean ratio5.2
Seven long-term survivors94,000b 69,000b 1.4
Nine rapid progressors89,000b 62,000b 1.4
PC04100,00076,0001.3
PC05325,000240,0001.4
  • a Peak midpoint preinfection anti-gp120 titers are recorded for the 12 MN and SF-2 rgp120 vaccinees who became infected after receiving at least three rgp120 immunizations. Also shown are the mean anti-gp120 titers measured in groups of long-term survivors and rapid progressors of HIV-1 infection (12, 17) and the anti-gp120 titers in two putative transmitters of HIV-1 infection to two of the vaccinees near the time of transmission.

  • b Mean value.